CVS · CVS HEALTH Corp
Market Cap
$119.49B
Shares
1.28B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$92.92
Open$93.60
Day$92.85–94.15
52W close$70.08–110.60
Avg vol 30d7.7M
Short int16.8M · 1.3% float · 1.8d
Short vol21%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Moderate
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+8%
above
Price vs 50-day avg
−8%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
56%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−12%
trailing
6-month return
+19%
trailing
YTD return
+17%
this year
Relative strength
+5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $101 › 200d $86 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +321 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.32% of float · ▼ -9.9% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
2,072 holders — mid 3-yr range
Squeeze score
32
low risk · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
7%
contracting
EPS growth
−62%
Y/Y
Free cash flow
$7.8B
Valuation
P/E 24.7
in line
Buyback
$10.0B
remaining
Balance sheet
$43.8B
net debt
Quant / Vol
risk profile
Volatility
31%
annualized · 1-yr
Max drawdown
−16%
past year
ATR
2.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
GAAP diluted EPS
· full-year 2026
Initiated
$6.84 – $7.04
prior FY $1.39
midpoint +399.3% Y/Y
Cash flow from operations
· full-year 2026
at least $11.5B
Adjusted EPS
· full-year 2026
Raised
$7.90 – $8.10
May 6, 2026
$7.30 – $7.50
changed to
Aug 5, 2026
$7.90 – $8.10
Prior guidance
period ended
· from the 8-K filed Oct 29, 2025
Adjusted EPS
· 2025 Full-Year
$6.55 – $6.65
Cash flow from operations
· 2025 Full-Year
$7.5B – $8B
Guided vs delivered
· last 1 settled
GAAP diluted EPS
Year EndingDecember 31, 2025
guided $3.84 – $3.94
$1.39
Miss −64.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+8%
Bullish
Price vs 50-day avg
−8%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
56%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $101 › 200d $86 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +321 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.32% of float · ▼ -9.9% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
2,072 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $70
Now $93 · 56%
Range high $111
vs 200-day avg +8%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EPS non-GAAP | $5.16 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted income attributable to CVS Health non-GAAP | $6.62B | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted operating income non-GAAP | 10.31B | Six Months Ended June 30, 2026 | — |
|
|
|||
| Days claims payable | 41.7 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Medical benefit ratio | 86% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Medical membership | 26M | Three Months Ended June 30, 2026 | — |
| Medical membership (ASC) | 16.19M | June 30, 2026 | — |
| Medical membership (Insured) | 9.83M | June 30, 2026 | — |
| Pharmacy claims processed | 937.7M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Prescription volume | 6.9% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Prescriptions filled | 908.2M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Same store sales increase: Front Store | 1.1% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Same store sales increase: Pharmacy | 2.9% | the three months ended June 30, 2026 filing | — |
|
|
|||
| Same store sales increase: Total | 2.7% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted operating income (loss) non-GAAP | 5.15B | Three Months Ended March 31, 2026 | — |
| Cash flow from operations | 4.2B | Three Months Ended March 31, 2026 | — |
| Commercial medical membership | 18.33M | Q1 2026 | — |
| Medicaid membership | 2.3M | Q1 2026 | — |
| Medicare Advantage membership | 4.18M | Q1 2026 | — |
| Medicare Prescription Drug Plan (stand-alone) membership | 3.89M | Q1 2026 | — |
| Medicare Supplement membership | 1.19M | Q1 2026 | — |
| Total medical membership | 26.01M | Q1 2026 | — |
| Adjusted operating income (loss) - Health Care Benefits non-GAAP | -$676M | Q4 FY2025 | — |
| Adjusted operating income - Health Services non-GAAP | $1.92B | Q4 FY2025 | — |
| Adjusted operating income - Pharmacy & Consumer Wellness non-GAAP | $1.91B | Q4 FY2025 | — |
| Adjusted operating loss - Corporate/Other non-GAAP | -$561M | Q4 FY2025 | — |
| MBR (Health care costs as a % of premium revenues) | 94.8% | Q4 FY2025 | — |
| People served through traditional, voluntary and consumer-directed health insurance products | 37M | As of December 31, 2025 | — |
| People served through traditional, voluntary and consumer-directed health insurance products and | 37M | As of December 31, 2025 | — |
| Pharmacy benefits manager plan members | 87M | As of December 31, 2025 | — |
| Retail pharmacy locations | 9,000 | As of December 31, 2025 | — |
| Walk-in and primary care medical clinics | 1,000 | As of December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVS
this stock
CVS HEALTH Corp
|
$119.49B | +17.1% | +7.8% | 24.7 | 1.3% |
|
UNH
Unitedhealth Group Inc
|
$359.94B | +19.7% | +11.8% | — | 1.7% |
|
ELV
Elevance Health, Inc.
|
$86.55B | +13.9% | +12.5% | 17.7 | 2.5% |
|
CI
Cigna Group
|
$74.06B | +0.9% | +11.2% | 11.6 | 2.0% |
|
HUM
Humana Inc
|
$47.14B | +53.3% | +10.1% | 41.9 | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVS | -0.8% | -11.7% | +19.3% | -11.0% | +17.1% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -1.9% | -15.7% | +4.6% | -14.2% | +4.0% |
Capital returns
Latest dividend
$0.665
/ share · ex Jul 23, 2026
Paid (TTM)
$2.66
/ share · 4 payouts
Dividend yield (TTM, derived)
2.86%
Buyback programs
· 2 active
· as of Jun 30, 2026
Authorized (total)
$20.00B
Spent (derived)
$10.00B
Remaining
$10.00B
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
64803
CUSIP
126650100
13F (30d)
1340 filings
1302 filers
Visit website
Investor relations